GILD - Gilead Sciences EV/EBITDA Multiple

Corporate company logo of Gilead Sciences (GILD)

Gilead Sciences, Inc. (GILD) is expanding its influence in oncology and infectious disease treatment, which is shaping the company's valuation trend based on EV/EBITDA. The global synthesis of components protects supplies from crises, while the modernization of plants guarantees the sterility of production. The current parameter is 15.61, capturing the volatility of market expectations and the operational resilience of the business to external shocks.

GILD Gilead Corp: Business Value to Operating Income Before Depreciation in the range 11/23/2025 - 11/18/2026

Analytical breakdowns for Gilead Sciences, Inc.

- stock price and consensus target price:
Basic company analysis:gilead.com GILD
Original product of gilead.com

Investing in Gilead Sciences, Inc. (GILD) requires deep analysis due to a high dependency on a narrow drug portfolio. The EV/EBITDA metric compares the total enterprise value of the business with its operating efficiency before taxes and depreciation. By analyzing the EV/EBITDA ratio in a historical context on GURU.Markets, an investor assesses market value relative to actual cash flow. A decline in this indicator may signal risks of losing patent protection or failures in oncology rather than a discount.

Analysis of competing companies

Cidara Therapeutics, Inc. - Enterprise Value to EBITDA Ratio|Novavax, Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CureVac NV - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Valneva Corp VALN|VIR (Vir Biotechnology Inc) - Enterprise Value to EBITDA Ratio|SIGA Technologies, Inc. - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization emergentbiosolutions.com|EV/EBITDA Multiple ateapharma.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Invivyd Corp (IVVD)|Total Company Value to Operating Income Before Depreciation Ratio Enanta Pharmaceuticals, Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Inovio Pharmaceuticals INO|Business Value to Operating Income Before Depreciation HLVX|Kalaris Tx - EV/EBITDA Multiple|Company Value to EBITDA dyadic.com|NanoViricides, Inc. (NNVC) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TLPH (Talphera Inc) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cocrystal|Enterprise Value to EBITDA Ratio trawspharma.com (TRAW)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Dogwood Therapeutics, Inc. (DWTX)|Total Company Value to Operating Income Before Depreciation Ratio Qualigen Therapeutics|EV/EBITDA Multiple ALVR (allovir.com)|EV/EBITDA Multiple VBI Vaccines Inc VBIV|VIRI: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation VXRT (vaxart.com)